NEW YORK – What is the best strategy for testing new drugs in patients with relatively rare cancer types? Is there an optimal treatment combination or sequence that might benefit one patient but not another? Which tumor targets are most apt to respond to treatment?
GNS Healthcare is banking on artificial intelligence to answer these and other questions for patients with multiple myeloma, a rare cancer marked by aberrant clonal expansions of antibody-producing white blood cells, known as plasma cells, that develop from B cells in the bone marrow.